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Angiotensinogen (AGT) is a component of the renin-angiotensin system, which plays a 
central role in blood pressure regulation.  Although it is controversial, the association 
between AGT gene polymorphisms and hypertension, and coronary heart disease is 
suspected.  In a case-control study on the metabolic syndrome, an association between 
AGT M235T polymorphism and serum total cholesterol (TC) level was demonstrated by 
Thomas et al. (2001).  To reconﬁrm this relationship, a cross-sectional study among Jap-
anese workers with 876 dyslipidemia and 1,158 non-dyslipidemia subjects was carried 
out.  To evaluate the AGT M235T polymorphism, a PCR-mutant allele speciﬁc ampliﬁ-
cation (MASA) method was employed.  No signiﬁcant difference in the distribution of ge-
netic variance was observed between the two groups.  Although it was not signiﬁcant, the 
T allele correlating to the lower TC of the present study occurred in a reversed manner 
to the previous report.  In our results, no signiﬁcant association between AGT M235T 
and TC was observed.
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Essential hypertension, a major part of hyperten-
sion, is a multifactorial disease and some candi-
date genes have been proposed.  The renin-angio-
tensin system (RAS) has a central role in regu-
lating blood pressure and sodium homeostasis. 
Angiotensinogen (AGT) plays a role in RAS as 
a substrate of renin and a precursor of angioten-
sin II.  For that reason, it was considered that the 
AGT gene polymorphism inﬂuenced blood pres-
sure, and the relationship between some polymor-
phisms and hypertension have been investigated 
since 1992 (Jeunemaitre et al., 1992; Caulﬁeld et 
al., 1994; Hata et al., 1994; Tiret et al., 1995; Sato 
et al., 1997; Ishigami et al., 1997, 1999; Ishikawa 
et al., 2001; Tiago et al., 2002; Vasku et al., 2002). 
In particular, the AGT gene M235T polymor-
phism, with an amino acid substitution of methio-
nine (M) to threonine (T) at codon 235, has been 
demonstrated to be associated not only with hy-
pertension, but also myocardial infarction (Tiret et 
Abbreviations: AGT, angiotensinogen; BMI, body mass index; CI, conﬁdence interval; DBP, diastolic blood pressure; 
FBS, fasting blood sugar; HDL, high-density lipoprotein cholesterol; MASA, mutant allele speciﬁc ampliﬁcation; MM, 
genotype M235M; MT, genotype M235T; M235T, mutation to the threonine of the methionine in amino acid codon 235; 
OR, odds ratio; RAS, renin-angiotensin system; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride; TT, 
genotype T235T
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al., 1995; Frossard et al., 1998; Fernandez-Arcas 
et al., 2001; Buraczynska et al., 2003).  Although 
the relationships are controversial (Fornage et al., 
1995; Hingorani et al., 1996; Ichihara et al., 1997; 
Arnett et al., 1998; Fernandez-Llama et al., 1998; 
Wang et al., 1999; Rodrigues-Perez et al., 2000; 
Nair et al., 2003), a hypothesis that the T235 al-
lele plays a role as a “thrifty gene” was proposed 
by comparing the genotype distribution of anthro-
poid and human ethnicities (Inoue et al., 1997).
 In the current clinical situation, patients with 
both hypertension and dyslipidemia were com-
monly observed.  Moreover, the metabolic syn-
drome, in which hypertension is clustered together 
with obesity, dyslipidemia and insulin resistance 
in an individual (WHO, 1999; NCEP ATP III, 
2001), has reached epidemic proportions, even in 
Japan.
 In such situations, the association between 
the AGT gene M235T polymorphism and serum 
total cholesterol level (TC) was demonstrated in a 
hospital-based case-control study on the metabol-
ic syndrome (Thomas et al., 2001).  The mecha-
nism by which RAS inﬂuences the lipid metabo-
lism directly has not been discovered (Nishimura 
et al., 1995; Wierzbicki et al., 2000; Singh et al., 
2003; Strazzullo et al., 2004).  However, this as-
sociation is remarkable, whether or not AGT plays 
any role as the candidate gene responsible for the 
metabolic syndrome.
 Therefore, we planned to evaluate the re-
lationship between the AGT gene M235T poly-
morphism and serum lipids more closely to the 
general population than the previous report.  For 
this purpose, a relatively large sample-size work-
site based cross-sectional study was carried out.
Subjects and Methods
Ethical issues
The present study was approved by the Ethics 
Committee of the Faculty of Medicine, Tottori 
University (No. 81, 2000).  Written informed 
consent of gene analysis was obtained from each 
study subject.
 
Study population and eligible subjects
The study population was recruited from workers 
of a company who received annual health check-
ups in 1998, in Shimane Prefecture in Western 
Japan.  Among the study population of our study, 
individuals who gave informed consent were cho-
sen as eligible subjects for the present study.
 
Various measurements
The body mass index (BMI), body weight in ki-
lograms divided by height in meters squared, was 
used as a measure of body composition.  Obesity 
was defined as a BMI of 25 and over.  Blood 
pressure was measured using a standard mercury 
sphygmomanometer.  Hypertension was defined 
as a systolic blood pressure (SBP) of 140 mmHg 
and over and/or a diastolic blood pressure (DBP) 
of 90 mmHg and over.  Blood samples were col-
lected from a peripheral vein.  Serum total cho-
lesterol (TC), high-density lipoprotein cholesterol 
(HDL), triglyceride (TG) and fasting blood sugar 
(FBS) were measured using an autoanalyzer 
(Model 7150 Autoanalyzer, Hitachi).  TC, HDL, 
TG and FBS were determined enzymatically us-
ing commercial enzyme kits (cholesterol oxidase 
method, direct method, free glycerol without 
blank method, Kyowa Medex, Tokyo, Japan; and 
the hexokinase glucose-6-phosphatedehydroge-
nase method, Wako, Tokyo, Japan, respectively). 
Details of these measurements have been de-
scribed previously (Kaetsu et al., 2004).
 In the present study, dyslipidemia was de-
ﬁned as at least one of the following three criteria: 
TC 220 mg/dL and over, HDL less than 40 mg/
dL, or TG 150 mg and over.  Hyperglycemia was 
deﬁned as FBS 110 mg/dL and over, as a substi-
tute for insulin resistance.
 Alcohol drinking and smoking habits were 
assessed using a questionnaire on lifestyle factors 
at annual health checkups.  Drinkers were deﬁned 
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as daily drinkers, and occasional and never drink-
ers were assessed as non-drinkers.  Smokers were 
defined as current smokers, and past and never 
smokers were assessed as non-smokers.
 
Identification of the AGT gene M235T 
polymorphism and genotyping
Genome DNA was extracted using a fully auto-
matic nucleic acid extractor (MagExtractor Ge-
nome, Toyobo, Osaka, Japan).  The PCR mutant 
allele specific amplification (MASA) method 
was employed to analyze the AGT gene M235T 
polymorphism and genotyping, M235M (MM), 
M235T (MT) and T235T (TT), respectively. 
Details of the molecular approach of this study 
have been described previously (Kishimoto et al., 
2001a, 2001b).
 Because there was quite a small proportion 
of the MM genotype (3.8, 30.6 and 65.6% for 
MM, MT and TT, respectively), genotype speciﬁc 
evaluation was performed in three genotypes, and 
MM and MT were combined against TT.
 
Statistical analysis
The software SAS (SAS Institute, Cary, NC) was 
employed for all statistical analysis.  The eligible 
subjects were divided into two groups according 
to dyslipidemia to compare the AGT gene M235T 
genotype distribution using a Mantel-Haenszel 
chi-square test.  The unpaired analysis of results 
using a Kruskal-Wallis test was performed to as-
sess whether the differences of the quantitative 
variables between genotypes were significant. 
These analyses were performed on all the sub-
jects, sex and age speciﬁcally.  According to the 
“Guidelines for Diagnosis and Treatment of Ath-
erosclerotic Cardiovascular Disease 2002” of the 
Japan Atherosclerosis Society (Saito, 2004), eli-
gible subjects were divided into younger and older 
groups with cutoff ages of 45 for males and 55 
for females.  Moreover, univariate and multivari-
ate unconditional logistic regression analysis was 
employed to evaluate the relationship between the 
AGT M235T genotype and the prevalence of ab-
normalities in each serum lipid.
 
Results
 
The total number of eligible subjects was 2,034, 
with 1,137 male and 897 female subjects, respec-
tively.  The descriptive characteristics of the sub-
jects are shown in Table 1.  Of the 2,034 subjects, 
876 were assigned to the dyslipidemia group and 
1,158 to the non-dyslipidemia group (Control 
group).  In the dyslipidemia group, a higher mean 
age, higher proportion of male subjects, obesity, 
hypertension, hyperglycemia, alcohol drinkers, 
and smokers were observed than in the control 
group.
 The distributions of genotype and allele 
frequency are shown in Table 2.  The relative 
frequencies of MM, MT and TT genotypes were 
4%, 31% and 65%, respectively.  The allele fre-
quencies were 19% and 81% for M and T alleles, 
respectively.  These results are consistent with 
the Hardy-Weinberg equilibrium, not only for 
the total subjects, but also when divided accord-
ing to the presence of dyslipidemia.  Neither the 
genotype nor the allele frequency showed statistic 
signiﬁcance between the dyslipidemia and control 
groups.
 The differences of quantitative variables be-
tween genotypes are shown in Table 3.  Although 
it was not signiﬁcant, the subjects carrying the M 
allele had higher TC.  On the other hand, no such 
differences were seen in either HDL or TG.
 The relationships between genotype and dys-
lipidemia and its components estimated by uncon-
ditional logistic regression analysis are shown in 
Table 4.  No signiﬁcant relationship was observed, 
both in univariate and multivariate analysis.
 
Discussion
 
The relative frequencies of the AGT gene M235T 
polymorphism in all eligible subjects were 4, 31 
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and 65% for the MM, MT and TT genotypes, 
respectively.  Although it was not signiﬁcant, the 
subjects carrying the M allele had higher TCs. 
No signiﬁcant relationship was observed, both in 
univariate and multivariate unconditional logistic 
regression analysis.
 The genotype distribution of this polymor-
phism of the present study was close to the result 
reported by Thomas et al. (2001).  Since the ethni-
cally different genotype distribution of this poly-
morphism has been reported (Rodriguez-Perez et 
al., 2000), it may represent the ethnic proximity 
in the genetic backgrounds between the two study 
populations.  On the other hand, the relationship 
between the polymorphism and TC occurred in a 
reversed manner.  They reported that the subjects 
Table 1.  Descriptive characteristics 
 Control Dyslipidemia Total P
Number of subjects  1158 876 2034 
Male subjects (%) 48.3% 66.0% 55.9% < 0.0001
Older subjects; age ≥ 45 in males, ≥ 55 in females 
 Ratio (%) 24.9% 42.2% 31.9% < 0.0001
 Age, mean ± SD (year) 40.3 ± 11.6  45.3 ± 10.3  42.4  ± 11.3  < 0.0001
Obese subjects; BMI > 25
 Ratio (%) 16.3% 34.7% 23.9% < 0.0001
 BMI, mean ± SD  22.1 ±  3.1  23.8 ±  3.0  22.9  ±  3.2  < 0.0001
Hypertension;  SBP ≥ 140 and/or DBP ≥ 90 mmHg
 Occurence ratio (%) 13.7% 28.5% 19.8% < 0.0001
 SBP ≥ 140 mmHg
      Occurence ratio (%) 10.2% 20.5% 14.5% < 0.0001
      Mean ± SD (mmHg) 116.8 ± 16.6  125.2 ± 17.5  120.4  ± 17.5  < 0.0001
 DBP ≥ 90 mmHg
      Occurence ratio (%) 9.8% 21.5% 14.7% < 0.0001
      Mean ± SD (mmHg) 72.6 ± 11.5  78.8 ± 12.2  75.2 ± 12.2  < 0.0001
Dyslipidemia
 Occurence ratio (%) 0.0% 100.0% 43.1%
 TC ≥ 220 mg/dL
      Occurence ratio (%) – 74.3% 32.0%
      Mean ± SD (mg/dL) 184.0 ± 22.4  232.5 ± 36.9  204.9 ± 38.1  < 0.0001
 HDL < 40 mg/dL
      Occurence ratio (%) – 11.2% 4.8% 
      Mean ± SD (mg/dL) 66.7 ± 14.7  62.0 ± 19.3  64.7 ± 17.0  < 0.0001
 TG ≥ 150 mg/dL
      Occurence ratio  (%) – 43.7% 18.8%
      Mean ± SD (mg/dL) 74.5 ± 29.7  158.7 ± 108.1  110.8 ± 85.3  < 0.0001
Hyperglycemia; FBS ≥ 110 mg/dL
      Occurence ratio  (%) 8.9% 16.7% 12.2% < 0.0001
      Mean ± SD (mg/dL) 96.5 ± 13.7  102.0 ± 21.8  98.8 ± 17.8  < 0.0001
Alcohol drinking
 Current ratio (%) 23.9% 34.7% 28.6% < 0.0001
Smoking
  Current ratio (%) 30.1% 42.1% 35.3% < 0.0001
Dyslipidemia:  at least one of the following features:  TC ≥ 220, HDL < 40 and TG ≥ 150 mg/dL.  
BMI, body mass index; DBP, diastolic blood pressure; FBS, fasting blood sugar; HDL, high density lipoprotein-colesterol; 
SBP, systolic blood pressure; TC,  total cholesterol; TG, triglyceride. 
P: P value for difference between dyslipidemia and control subjects.  
 P values were determined by chi-square (sex, older, obese, hypertension, dyslipidemia, hyperglycemia, alcohol drinking 
and smoking) and Wilcoxon rank sum test (age, BMI, TC, HDL, TG and FBS).
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Table 2.  Angiotensinogen M235T genotypes and allele frequencies with dyslipidemia
 Control Dyslipidemia Total P
All subjects
 Number   1158  876  2034
 Genotype T/T  770 ( 66.5) 564 ( 64.4) 1334 ( 65.6)
  M/T 344 ( 29.7) 278 ( 31.7) 622 ( 30.6)
  M/M 44 (   3.8) 34 (   3.9) 78 (   3.8) 0.3816 
   M/T + M/M 388 ( 33.5) 312 ( 35.6) 700 ( 34.4) 0.3447†
 Allele frequency T allele 1884 ( 81.3) 1406 ( 80.3) 3290 ( 80.9)
  M allele 432 ( 18.7) 346 ( 19.7) 778 ( 19.1) 0.3788 
Male subjects
 Number   559  578  1137
 Genotype T/T  389 ( 69.6) 374 ( 64.7) 763 ( 67.1)
  M/T 150 ( 26.8) 191 ( 33.1) 341 ( 30.0)
  M/M 20 (   3.6) 13 (   2.2) 33 (   2.9) 0.9224
   M/T + M/M 170 ( 30.4) 204 ( 35.3) 374 ( 32.9) 0.0913†
 Allele frequency T allele 928 ( 83.0) 939 ( 81.2) 1867 ( 82.1)
  M allele 190 ( 17.0 ) 217 ( 18.8) 407 ( 17.9) 0.2778 
Female subjects
 Number   599  298  897
 Genotype T/T  381 ( 63.6) 190 ( 63.8) 571 ( 63.7)
  M/T 194 ( 32.4) 87 ( 29.2) 281 ( 31.3)
  M/M 24 (   4.0) 21 (   7.0) 45 (   5.0) 0.4868 
   M/T + M/M 218 ( 36.4) 108 ( 36.2) 326 ( 36.3) 1.0000†
 Allele frequency T allele 956 ( 79.8) 467 ( 78.4) 1423 ( 79.3)
  M allele 242 ( 20.2) 129 ( 21.6) 371 ( 20.7) 0.4769 
Younger subjects; age < 45 in males, < 55 in females
 Number   879  506  1385
 Genotype T/T  572 ( 65.1) 326 ( 64.4) 898 ( 64.8)
  M/T 271 ( 30.8) 161 ( 31.8) 432 ( 31.2)
  M/M 36 (   4.1) 19 (   3.8) 55 (   4.0) 0.9224 
   M/T + M/M 307 ( 34.9) 180 ( 35.6) 487 ( 35.2) 0.8537†
 Allele frequency T allele 1415 ( 80.5) 813 ( 80.3) 2228 ( 80.4)
  M allele 343 ( 19.5) 199 ( 19.7) 542 ( 19.6) 0.9220 
Older subjects; age < 45 in males, < 55 in females
 Number   279  370  649
 Genotype T/T  98 ( 71.0) 238 ( 64.3) 436 ( 67.2)
  M/T 73 ( 26.2) 117 ( 31.6) 190 ( 29.3)
  M/M 8 (   2.9) 15 (   4.1) 23 (   3.5) 0.0727 
   M/T + M/M 81 ( 29.0) 132 ( 35.7) 213 ( 32.8) 0.0891†
 Allele frequency T allele 469 ( 84.1) 593 ( 80.1) 1062 ( 81.8)
    M allele 89 ( 15.9)  147 ( 19.9) 236 ( 18.2)  0.0702  
P: P value for difference between dyslipidemia and control subjects.  
 P values were determined by chi-square test.
† Compared to T/T.
carrying the M allele of the AGT gene M235T 
polymorphism (MM/MT) had signiﬁcantly lower 
TC than those with the TT genotype.  Further-
more, a linear dose-dependent relationship be-
tween the genotypes for TC was demonstrated. 
However, our result showed that the M allele had 
higher TC, though it was not significant.  Ac-
cording to other investigations, which described 
the relationship between the AGT gene M235T 
polymorphism and TC, some reported the M al-
lele had lower TC, equivalent to Thomas et al. 
(Iwai et al., 1995; Nishimura et al., 1995; Batalla 
A. Kaetsu et al.
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Table 3.  Mean value of serum lipids and other variables according to AGT M235T genotype 
 TT MT MM MT + MM P P† 
All subjects
 Number   1334   622   78   700
 TC (mg/dL) 203.6 ±  36.2  206.6 ±  41.6  213.2 ±  39.3  207.4 ±  41.4  0.1816  0.2627
 HDL (mg/dL) 64.7 ±  17.2  64.6 ±  16.6  65.1 ±  16.7  64.7 ±  16.6  0.9998  0.9855
 TG (mg/dL) 108.7 ±  79.5  116.1 ±  97.8  102.7 ±  70.9  114.6 ±  95.2 0.5886  0.3853
 BMI (kg/m2) 23.0 ±  3.2  22.6 ± 3.2  22.7 ± 3.1  22.6 ±  3.2  0.0687  0.0219
 SBP (mmHg) 120.8 ±  17.3  120.1 ±  17.9  116.0 ±  17.9  119.7 ±  17.9  0.0464  0.0992
 DBP (mmHg) 75.5 ±  12.0  72.0 ±  12.6  73.4 ±  11.9  74.8 ±  12.5  0.2767  0.2311
 FBS (mg/dL) 99.0 ±  18.1  98.7 ±  17.7  97.7 ±  13.5  98.6 ±  17.2  0.6635  0.3669
Male subjects
 Number   763   341   33   374
 TC (mg/dL) 203.0 ±  36.0  210.6 ±  41.5  204.5 ±  35.5  210.1 ±  41.0  0.0493  0.0199
 HDL (mg/dL) 59.6 ±  16.4  60.0 ±  15.6  62.1 ±  17.2  60.2 ±  15.8  0.6789  0.4419
 TG (mg/dL) 132.8 ±  91.1  146.3 ±  112.7  117.6 ±  94.9  143.8 ±  111.5  0.0304  0.1651
 BMI (kg/m2) 23.6 ±   3.1  23.3 ±   3.1  23.1 ±   2.6  23.3 ±   3.1  0.4347  0.2227
 SBP (mmHg) 124.8 ±  16.5  124.8 ±  16.1  119.4 ±  18.8  124.3 ±  16.4  0.2026  0.6368
 DBP (mmHg) 78.6 ±  11.9  78.6 ±  12.1  76.1 ±  13.1  78.3 ±  12.2  0.4510  0.8568
 FBS (mg/dL) 101.9 ±  20.6  101.8 ±  20.0  97.7 ±   9.9  101.5 ±  19.4  0.5062  0.3140
Femle subjects
 Number   571   281   45   326
 TC (mg/dL) 204.4 ±  36.4  201.8 ±  41.3  219.6 ±  41.0  204.3 ±  41.7  0.0112  0.3879
 HDL (mg/dL) 71.4 ±  15.9  70.3 ±  16.1  67.3 ±  16.1  69.9 ±  16.1  0.1077  0.1030
 TG (mg/dL) 76.6 ±  43.3  79.4 ±  57.5  91.8 ±  44.2  81.1 ±  56.0  0.0238  0.3963
 BMI (kg/m2) 22.2 ±   3.2  21.8 ±   3.1  22.4 ±   3.5  21.9 ±   3.2  0.1890  0.1328
 SBP (mmHg) 115.5 ±  16.9  114.5 ±  18.4  113.5 ±  17.0  114.4 ±  18.2  0.3018  0.1225
 DBP (mmHg) 71.2 ±  10.8  70.7 ±  11.9  71.4 ±  10.6  70.8 ±  11.7  0.5097  0.3788
 FBS (mg/dL) 95.1 ±  13.2  94.8 ±  13.3  97.8 ±  15.7  95.2 ±  13.7  0.6507  0.5979
Younger subjects; age < 45 in males, < 55 in females
 Number   898   432   55   487
 TC (mg/dL) 200.3 ±  35.9  201.2 ±  40.7  205.5 ±  38.1  201.7 ±  40.4  0.7019  0.8596
 HDL (mg/dL) 66.7 ±  17.2  66.1 ±  16.8  64.5 ±  15.8  65.9 ±  16.6  0.5044  0.3683
 TG (mg/dL) 98.3 ±  76.4  101.6 ±  83.0  96.8 ±  80.8  101.0 ±  82.7  0.9211  0.7287
 BMI (kg/m2) 22.6 ±   3.2  22.2 ±   3.2  22.2 ±   3.1  22.2 ±   3.2  0.1028  0.0331
 SBP (mmHg) 116.5 ±  15.3  115.6 ±  15.7  111.9 ±  15.1  115.2 ±  15.7  0.0843  0.1141
 DBP (mmHg) 72.2 ±  10.7  71.5 ±  11.5  70.7 ±  10.7  71.4 ±  11.4  0.2103  0.0869
 FBS (mg/dL) 95.9 ±  12.1  95.3 ±  12.6  93.8 ±   8.3  95.1 ±  12.2  0.3450  0.1565
Older subjects; age ≥ 45 in males, ≥ 55 in females
 Number   436   190   23   213
 TC (mg/dL) 210.3 ±  35.8  219.0 ±  40.9  231.7 ±  36.4  220.4 ± 40.6  0.0066  0.0061
 HDL (mg/dL) 60.4 ±  16.3  61.4 ±  15.9  66.5 ±  18.8  62.0 ± 16.3  0.3899  0.3278
 TG (mg/dL) 130.3 ±  81.5  149.2 ± 118.9  116.9 ±  35.7  145.7 ±  113.3  0.1801  0.0720
 BMI (kg/m2) 23.7 ±   3.0  23.5 ±   3.0  23.9 ±   2.9  23.6 ± 3.0  0.5198  0.5649‡
 SBP (mmHg) 129.7 ±  17.7  130.3 ±  18.4  125.7 ±  20.4  129.8 ± 18.6  0.7307  0.9190 
 DBP (mmHg) 82.1 ±  11.9  83.0 ±  11.3  79.9 ±  12.1  82.7 ± 11.4  0.3635  0.4073
  FBS (mg/dL) 105.4 ±  25.4  106.5 ±  24.0  107.2 ±  18.3  106.5 ± 23.4  0.3694  0.2070 
 P:  P value for difference between TT versus MT versus MM by Kruskal-Wallis test.
 P†: P value for differences between TT versus MT + MM by Wilcoxon rank sum test.
   ‡ P value for differences between TT versus MT + MM by Student’s t-test
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Table 4.  Odds ratios of AGT M235T genotype for dyslipidemia
 Univariate  Multivariate†
 
+  –
  OR  95% CI P OR 95% CI P
Dyslipidemia
 TT 564 770 1.00        1.00 
 MT 278 344 1.10  0.91  – 1.34  0.3140  1.22  0.99  – 1.50  0.0585
 MM 34 44 1.06  0.67  – 1.67  0.8200  1.20  0.74  – 1.97  0.4609
      P‡                0.3816
 TT 564 770 1.00        1.00
 MT + TT 312 388 1.10  0.91  – 1.32  0.3204  1.22  1.00  – 1.49  0.0508 
      P‡                0.3447
TC, ≥ 220 mg/dL
 TT 416 918 1.00        1.00 
 MT 205 417 1.09  0.89  – 1.33  0.4326  1.16  0.94  – 1.43  0.1758
 MM 30 48 1.38  0.86  – 2.21  0.1806  1.42  0.87  – 2.31  0.1633
      P‡               0.1742
 TT 416 918 1.00        1.00 
 MT + TT 235 465 1.12  0.92  – 1.36  0.2730  1.18  0.97  – 1.45  0.1017
      P‡               0.2730 
HDL, < 40 mg/dL
 TT 68 1266 1.00        1.00 
 MT 28 594 0.88  0.56  – 1.38  0.5702  0.95  0.60  – 1.50  0.8192
 MM 2 76 0.49  0.12  – 2.04  0.3265  0.66  0.16  – 2.82  0.5781
      P‡               0.3101
 TT 68 1266 1.00        1.00 
 MT + TT 30 670 0.83  0.54  – 1.29  0.4173  0.92  0.59  – 1.44  0.7191
      P‡               0.4168
TG, ≥ 150 mg/dL
 TT 248 1086 1.00        1.00 
 MT 125 497 1.10  0.87  – 1.40  0.4300  1.21  0.93  – 1.57  0.1631
 MM 10 68 0.64  0.33  – 1.27  0.2033  0.89  0.43  – 1.82  0.7415
      P‡               0.8794
 TT 248 1086 1.00        1.00 
 MT + TT 135 565 1.05  0.83  – 1.32  0.7020  1.17  0.91  – 1.52  0.2238
      P‡               0.7033
Dyslipidemia:  at least one of the following features:  TC ≥ 220, HDL < 40 and TG ≥150 mg/dL.
CI, conﬁdence interval; OR, ddds ratio.
† Adjusted for sex, age, BMI, FBS, alcohol and smoking.  
‡ P for chi-square. 
et al., 2000), and some reported the M allele had 
higher TC, equivalent to our ﬁndings (Matsubara 
et al., 2003), others still showed no relationship 
(Iwai et al., 1994; Katsuya et al., 1995; Hingorani 
et al., 1996; Fujiwara et al., 2002; Robinson et 
al., 2004).  Because the relationship between this 
polymorphism and TC was not stable among the 
investigations, and the mechanism by which RAS 
influences the lipid metabolism directly has not 
been discovered (Nishimura et al., 1995; Wierz-
bicki et al., 2000; Singh et al., 2003; Strazzullo et 
al., 2004), the relationship may in fact be weak or 
even nonexistent.
 Although this work-site cross-sectional study 
was employed to investigate the relationship be-
tween the AGT gene M235T polymorphism and 
serum lipids more closely to general population 
than a hospital-based case-control study, some 
limitations remain in this study.  First, the pres-
ence of the healthy worker’s effect was suspected. 
The possibility that the exclusion of unhealthy 
subjects from the study population inﬂuenced the 
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result cannot be denied.  Second, the relation-
ships among study subjects were not conﬁrmed. 
The possibility that relatives and siblings showed 
similar characteristics and inﬂuenced the results 
cannot be denied.  Third, the present and past 
illnesses of each subject were not evaluated.  Be-
cause our data originated from the work-site, the 
history of each subject was not obtained in more 
detail than the hospital-based data.  However, in 
the current clinical situation of Japanese hyper-
tension therapy, medication is administered sub-
sequent to lifestyle modification (Saruta, 2005). 
That lifestyle modification improves cardiovas-
cular risk factors, including serum lipids among 
general population, has been reported (Okazaki 
et al., 2001).  Furthermore, it was reported that 
the subjects with the TT homozygote of the AGT 
M235T genotype had a higher prevalence of anti-
hypertension medication among middle-aged 
Japanese men (Nishimura et al., 1995).  By not 
considering the present and past history of each 
subject, the possibility that the underestimation of 
the serum lipids of the subjects carrying the T al-
lele cannot be denied.  A prospective cohort study 
should be performed for a more conclusive evalu-
ation.
Conclusion
The association between the AGT gene M235T 
polymorphism and serum lipids among Japanese 
workers was investigated.  Although it was not 
signiﬁcant, subjects carrying the M allele of the 
AGT gene M235T polymorphism (MM/MT) had 
higher TC than those with the TT genotype.  The 
AGT gene M235T polymorphism showed no sig-
nificant association between serum lipids in our 
study population.
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